Professional technology integration to support the entire R&D process

Immuno-oncology (I-O) assay development aims to establish reproducible functional analysis methods to quantitatively assess the interaction between immune cells and tumor cells, supporting the discovery and optimization of immunomodulatory drugs. Similar to GPCR assays, its core is to construct an experimental system that can simulate key biological processes and generate reliable signal outputs.

1.Target and Mechanism Definition

Identify the Target: Determine the immune pathway to be intervened (e.g., immune checkpoints such as PD-1/PD-L1, CTLA-4; CD3 bispecific antibodies; activating receptors such as 4-1BB).

Define the Biological Output: Based on the mechanism of action, determine the core functional readings to be measured, such as T cell activation (CD69/CD25 expression, cytokine secretion), tumor cell killing, or immune checkpoint blockade effects.

Determine the Assay Objective: Clarify whether it is for agonist/antagonist screening, antibody efficacy evaluation, or synergistic effect studies of combination therapies.

2.Cell Co-culture System Construction

Effective Cell Selection and Preparation: 

Primary Immune Cells: Isolate T cells or NK cells from healthy donor PBMCs. These have high physiological relevance, but donor mutations must be considered. Pre-activation (e.g., using CD3/CD28 antibodies) is often required.

Engineered Effector Cells: Such as reporter gene Jurkat T cells (e.g., NFAT-luciferase) or NK-92 cells overexpressing specific receptors. They offer good homogeneity and are suitable for initial screening.

Target Cell Selection and Engineering:

Select tumor cell lines expressing the target antigen (e.g., tumor-associated antigen) and corresponding ligand (e.g., PD-L1).

Target cells are typically stabilized and transfected with luciferase (Luc) or fluorescent proteins (e.g., GFP) to facilitate real-time, quantitative monitoring of the killing effect.

Co-culture Condition Optimization: Optimize the effector-to-target ratio, co-culture time, and culture medium composition (e.g., IL-2 addition) to balance signal intensity and background.

3.Detection Method Development and Optimization

Detection Technology Matching: Select the most direct and least interfering detection technology based on the defined biological output (see the table in Part II).

Key Parameter Optimization: 

Cell State: Ensure high effector cell activity and target cells are in the logarithmic growth phase.

Stimulation Conditions: Optimize antibody/drug concentration and incubation time.

Detection Window: Maximize the signal-to-noise ratio using positive controls (e.g., anti-CD3 antibody for T cell activation, target cells highly expressing antigen for killing).

Control Setup: Must include a maximum effector control, a background control (effector cells only or target cells only), and an isotype antibody control.

4.Analytical Method Establishment and Validation

Data Analysis: Calculate parameters such as specific killing rate, activation fold, EC50/IC50, etc.

Performance Validation: Evaluate the sensitivity (ability to detect weak activity), specificity (signal-dependent target interaction), precision (intra- and inter-plate CV), and robustness of the assay.

Challenge 1: High Background Signal (Non-specific Killing or Activation)

Solution:

1.Optimize the effector-to-target ratio to reduce non-specific effects caused by effector cell overload.

2.Use isotype control antibodies to accurately set the background threshold.

3.Co-culturing in serum-free or low-serum media reduces stimulation from unknown components.

Challenge 2: High inter-donor/inter-experimental variability

Solution:

1.Use mixed multi-donor PBMCs to average individual differences.

2.Normalize data to in-plate positive controls (e.g., using "% of Control" or "stimulation index"). 

3.Establish frozen, batch-produced immune cell banks to ensure consistency of experimental materials.

Challenge 3: Insufficient physiological relevance of the model 

Solution: 

1.Use patient-derived primary immune cells with autologous tumor cells for critical validation, but throughput is low.

2.Use 3D tumor spheroids co-cultured with immune cells to better simulate the physical barriers and microenvironment of solid tumors.

Successful immuno-oncology assay development begins with the precise definition of the mechanism of action and the required functional readouts. The core lies in constructing a co-culture system with clear signals, controllable background, and good reproducibility. A reasonable balance and phased application between the high-throughput screening advantages of engineered reporter cell lines and the physiological relevance of primary cell models is key to accelerating I-O drug discovery. A well-optimized I-O assay is an indispensable tool for evaluating the function of candidate molecules and elucidating their mechanisms of action.